Dr. Kaufman Discusses Durable Responses to Avelumab in Merkel Cell Carcinoma
May 18th 2017Howard L. Kaufman, MD, a surgical oncologist at Rutgers Cancer Institute of New Jersey, discusses a study which showed further durable responses to avelumab (Bavencio) in patients with merkel cell carcinoma who progressed after chemotherapy.
Watch
Projecting Cancer Incidence in HIV-Positive Population in the US Through 2030
May 17th 2017Jessica Islam, MPH, a PhD student at the University of North Carolina at Chapel Hill Gillings School of Global Public Health, discusses research that projected cancer incidence in the HIV-positive population in the United States through 2030.
Watch
Exploring Vaccination in Low-Grade Glioma With the Aim of Preventing High-Grade Transformation
May 17th 2017Hideho Okada, MD, PhD, director, Brain Tumor Immunotherapy Center, professor of Neurological Surgery, University of California, San Francisco, discusses a study exploring vaccination in low-grade glioma aiming at prevention of high-grade transformation.
Watch
Why CheckMate-026 Failed to Show PFS Improvement With Nivolumab in Lung Cancer
May 16th 2017Julie R. Brahmer, MD, associate professor of Oncology, Bloomberg Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, discusses why CheckMate-026 was not successful in showing an improvement in progression-free survival (PFS) for patients with advanced non-small cell lung cancer.
Watch
Results of Buparlisib Plus Fulvestrant in HR+/HER2- Breast Cancer
May 15th 2017Ruth O’Regan, MD, discusses results of BELLE-3, a phase III study of buparlisib (BKM120) plus fulvestrant (Faslodex) in postmenopausal women with hormone receptor (HR)-positive, HER2-negative breast cancer.
Watch